SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 15, 1997
MIRAVANT MEDICAL TECHNOLOGIES
(Exact name of registrant as specified in its charter)
Delaware 0-25544 77-0222872
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
7408 Hollister Avenue
Santa Barbara, California 93117
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 805/685-9880
PDT, INC.
(Former name or former address, if changed since last report)
The Exhibit Index is located on Page 2.
Page 1 of 5
<PAGE>
ITEM 5. OTHER EVENTS.
On September 15, 1997, Miravant Medical Technologies, a Delaware
corporation (the "Registrant"), issued a press release announcing that the
Registrant had changed its name from PDT, Inc. to Miravant Medical Technologies.
In the press release the Registrant also disclosed that the name change had been
approved by the board of directors and stockholders of the Registrant. A copy of
the press release is attached as an exhibit hereto and is incorporated by
reference in its entirety herein.
EXHIBITS
The following exhibit is filed as part of this report:
Exhibit Exhibit
Number Description
99.1 Press Release
Page 2 of 5
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MIRAVANT MEDICAL TECHNOLOGIES,
a Delaware corporation
(Registrant)
By: /s/ John M. Philpott
------------------------
Chief Financial Officer
Date: September 24, 1997
Page 3 of 5
<PAGE>
EXHIBIT 99
For more information please visit our web page at: www.miravant.com
Contacts: Nick Kormeluk Laurens Lichty
Sr. Manager, Investor Relations Manager, Corporate Communications
(805) 685-9880 (805) 685-9880
PDT, INC. CHANGES NAME TO MIRAVANT MEDICAL TECHNOLOGIES
NASDAQ TICKER SYMBOL BECOMES MRVT ON SEPTEMBER 16TH SANTA
BARBARA, CALIF., SEPTEMBER 15, 1997 -- PDT, Inc. (Nasdaq:PDTI) announced today
that its name is now Miravant Medical Technologies (Nasdaq:MRVT). All addresses
and phone numbers remain unchanged, except the web site which is
www.miravant.com and the Nasdaq ticker symbol which becomes MRVT at market open
on September 16th.
"The name Miravant is derived from the Latin root miracula (miraculous) and the
French avant (in front of) -- in front of the miracle, " stated Gary S. Kledzik,
Ph.D., chairman and chief executive officer of Miravant. "From our founding in
1989, we have dedicated ourselves to creating an advanced form of photoselective
medicine."
Miravant is branding its proprietary photoselective procedures and products as
PhotoPoint(TM). PhotoPoint, now in clinical trials, uses light-activated drugs
to selectively destroy diseased cells and tissues, and is being developed for a
broad range of disease applications.
"By working aggressively with our corporate partners to create a sharply-focused
brand identity among the medical and patient community, we intend to make
PhotoPoint synonymous with the highest standard of control in photoselective
procedures, " added Dr. Kledzik.
Miravant is a leader in developing both pharmaceuticals and devices for
photodynamic therapy, a medical procedure using light-activated drugs to
selectively destroy diseased cells and tissues. The company is pursuing
PhotoPoint applications in a number of medical specialties, including
(continued)
Page 4 of 5
<PAGE>
oncology, urology, dermatology, ophthalmology, cardiology and gynecology. Over
the last several years, Miravant has established strategic collaborative
relationships with select corporations, including Pharmacia & Upjohn, Boston
Scientific Corporation, Ramus Medical Technologies, Cordis, a Johnson & Johnson
company, and Iris Medical Corporation.
Except for the historical information contained herein, the matters discussed in
this news release are deemed forward-looking statements under federal securities
laws that involve risks and uncertainties. Actual results may differ materially
from those in the forward-looking statements depending on a number of factors
including, among other things, the ability to maintain long-term relationships
with corporate partners, the ability to bring products to market through the
regulatory approval process, uncertainty of future profitability, financing
requirements and other factors detailed from time to time in the Company's SEC
reports, including its report on Form 10-K for the fiscal year ended December
31, 1996.
# # #
Page 5 of 5
<PAGE>
